A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs CB 03 01 (Primary)
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Cassiopea
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
    • 15 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
    • 12 Nov 2015 According to a Cassiopea media release the trial has initiated and the first patient has been enrolled in the study in the USA. The MR also states that results from the study will be available in H2 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top